Defining Disease Severity in Inflammatory Bowel Diseases: Current and Future Directions

Clinical Gastroenterology and Hepatology

Volumn 14, Issue 3, 2016, Pages 348-354.e17

  Peyrin Biroulet, Laurent ^a   Panés, Julián ^b   Sandborn, William J ^c   Vermeire, Séverine ^d   Danese, Silvio ^e   Feagan, Brian G ^f   Colombel, Jean Frédéric ^g   Hanauer, Stephen B ^h   Rycroft, Beth ⁱ  

^a UNIVERSITÉ DE LORRAINE   (France)

^b HOSPITAL CLÍNIC   (Spain)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^e HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^f ROBARTS RESEARCH INSTITUTE   (Canada)

^g LILLE UNIVERSITY HOSPITAL   (France)

^h NORTHWESTERN UNIVERSITY   (United States)

ⁱ ABBVIE INC   (United States)

Author keywords

Disease Course; Disease Severity; Inflammatory Bowel Disease

Indexed keywords

C REACTIVE PROTEIN; CALGRANULIN; CORTICOSTEROID; LACTOFERRIN; NEOPTERIN;

ALGORITHM; ARTICLE; CLINICAL PRACTICE; CROHN DISEASE; DISABILITY; DISEASE ACTIVITY; DISEASE COURSE; DISEASE SEVERITY; ENDOSCOPY; FATIGUE; HISTOLOGY; HUMAN; INFLAMMATORY BOWEL DISEASE; OUTCOME ASSESSMENT; PROGNOSIS; QUALITY OF LIFE; SYMPTOM; ULCERATIVE COLITIS; UPPER GASTROINTESTINAL TRACT; CLINICAL MEDICINE; INFLAMMATORY BOWEL DISEASES; PATHOLOGY; PROCEDURES; SEVERITY OF ILLNESS INDEX;

CLINICAL MEDICINE; HUMANS; INFLAMMATORY BOWEL DISEASES; SEVERITY OF ILLNESS INDEX;

EID: 84958120391     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2015.06.001     Document Type: Article

References (187)

1. Best W.R., Becktel J.M., Singleton J.W., et al. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 1976, 70:439-444.
2. Schroeder K.W., Tremaine W.J., Ilstrup D.M. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 1987, 317:1625-1629.
3. Van Assche G., Dignass A., Panes J., et al. The second European evidence-based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis. J Crohns Colitis 2010, 4:7-27.
4. Dignass A., Eliakim R., Magro F., et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosis. J Crohns Colitis 2012, 6:965-990.
5. Thia K., Faubion W.A., Loftus E.V., et al. Short CDAI: development and validation of a shortened and simplified Crohn's disease activity index. Inflamm Bowel Dis 2011, 17:105-111.
6. Khanna R, D'Haens G, Feagan B, et al. Patient reported outcome measures derived from the Crohn's Disease Activity Index: correlation between PRO2 and PRO3 scores and CDAI-defined clinical thresholds (abstr). Presented at the 9th Annual Congress of the European Crohn's and Colitis Organisation, Copenhagen, Denmark, February, 22-24 2014; P176.
7. Harvey R.F., Bradshaw J.M. A simple index of Crohn's-disease activity. Lancet 1980, 1:514.
8. Best W.R. Predicting the Crohn's disease activity index from the Harvey-Bradshaw Index. Inflamm Bowel Dis 2006, 12:304-310.
9. Ricanek P., Brackmann S., Perminow G., et al. Evaluation of disease activity in IBD at the time of diagnosis by the use of clinical, biochemical, and fecal markers. Scand J Gastroenterol 2011, 46:1081-1091.
10. Jones J., Loftus E.V., Panaccione R., et al. Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease. Clin Gastroenterol Hepatol 2008, 6:1218-1224.
11. van Hees P.A., van Elteren P.H., van Lier H.J., et al. An index of inflammatory activity in patients with Crohn's disease. Gut 1980, 21:279-286.
12. Irvine E.J. Usual therapy improves perianal Crohn's disease as measured by a new disease activity index. McMaster IBD Study Group. J Clin Gastroenterol 1995, 20:27-32.
13. Peyrin-Biroulet L., Loftus E.V., Colombel J.F., et al. The natural history of adult Crohn's disease in population-based cohorts. Am J Gastroenterol 2010, 105:289-297.
14. Konig H.H., Ulshofer A., Gregor M., et al. Validation of the EuroQol questionnaire in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol 2002, 14:1205-1215.
15. Bernklev T., Jahnsen J., Lygren I., et al. Health-related quality of life in patients with inflammatory bowel disease measured with the Short Form-36: psychometric assessments and a comparison with general population norms. Inflamm Bowel Dis 2005, 11:909-918.
16. Williet N., Sandborn W.J., Peyrin-Biroulet L. Patient-reported outcomes as primary end points in clinical trials of inflammatory bowel disease. Clin Gastroenterol Hepatol 2014, 12:1246-1256 e6.
17. Irvine E.J. Development and subsequent refinement of the inflammatory bowel disease questionnaire: a quality-of-life instrument for adult patients with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 1999, 28:S23-S27.
18. Clara I., Lix L.M., Walker J.R., et al. The Manitoba IBD Index: evidence for a new and simple indicator of IBD activity. Am J Gastroenterol 2009, 104:1754-1763.
19. Surti B., Spiegel B., Ippoliti A., et al. Assessing health status in inflammatory bowel disease using a novel single-item numeric rating scale. Dig Dis Sci 2013, 58:1313-1321.
20. Bodger K., Ormerod C., Shackcloth D., et al. Development and validation of a rapid, generic measure of disease control from the patient's perspective: the IBD-control questionnaire. Gut 2014, 63:1092-1102.
21. Khanna R., Zou G., D'Haens G., et al. A retrospective analysis: the development of patient reported outcome measures for the assessment of Crohn's disease activity. Aliment Pharmacol Ther 2015, 41:77-86.
22. Peyrin-Biroulet L., Cieza A., Sandborn W.J., et al. Development of the first disability index for inflammatory bowel disease based on the international classification of functioning, disability and health. Gut 2012, 61:241-247.
23. Peyrin-Biroulet L. What is the patient's perspective: how important are patient-reported outcomes, quality of life and disability?. Dig Dis 2010, 28:463-471.
24. Florin T.H., Paterson E.W., Fowler E.V., et al. Clinically active Crohn's disease in the presence of a low C-reactive protein. Scand J Gastroenterol 2006, 41:306-311.
25. Denis M.A., Reenaers C., Fontaine F., et al. Assessment of endoscopic activity index and biological inflammatory markers in clinically active Crohn's disease with normal C-reactive protein serum level. Inflamm Bowel Dis 2007, 13:1100-1105.
26. Mary J.Y., Modigliani R. Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes Therapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). Gut 1989, 30:983-989.
27. Daperno M., D'Haens G., Van Assche G., et al. Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD. Gastrointest Endosc 2004, 60:505-512.
28. Panes J., Bouzas R., Chaparro M., et al. Systematic review: the use of ultrasonography, computed tomography and magnetic resonance imaging for the diagnosis, assessment of activity and abdominal complications of Crohn's disease. Aliment Pharmacol Ther 2011, 34:125-145.
29. Rimola J., Ordas I., Rodriguez S., et al. Magnetic resonance imaging for evaluation of Crohn's disease: validation of parameters of severity and quantitative index of activity. Inflamm Bowel Dis 2011, 17:1759-1768.
30. Beaugerie L., Seksik P., Nion-Larmurier I., et al. Predictors of Crohn's disease. Gastroenterology 2006, 130:650-656.
31. Loly C., Belaiche J., Louis E. Predictors of severe Crohn's disease. Scand J Gastroenterol 2008, 43:948-954.
32. Yarur A.J., Strobel S.G., Deshpande A.R., et al. Predictors of aggressive inflammatory bowel disease. Gastroenterol Hepatol (NY) 2011, 7:652-659.
33. Zallot C., Peyrin-Biroulet L. Clinical risk factors for complicated disease: how reliable are they?. Dig Dis 2012, 30(Suppl 3):67-72.
34. Pariente B., Mary J.-Y., Danese S., et al. Development of the Lémann index to assess digestive tract damage in patients with Crohn's disease. Gastroenterology 2015, 148:52-63.
35. D'Haens G., Sandborn W.J., Feagan B.G., et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology 2007, 132:763-786.
36. Truelove S.C., Witts L.J. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J 1955, 2:1041-1048.
37. Lewis J.D., Chuai S., Nessel L., et al. Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis. Inflamm Bowel Dis 2008, 14:1660-1666.
38. Sutherland L.R., Martin F., Greer S., et al. 5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology 1987, 92:1894-1898.
39. Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ 1989, 298:82-86.
40. Powell-Tuck J., Day D.W., Buckell N.A., et al. Correlations between defined sigmoidoscopic appearances and other measures of disease activity in ulcerative colitis. Dig Dis Sci 1982, 27:533-537.
41. Walmsley R.S., Ayres R.C., Pounder R.E., et al. A simple clinical colitis activity index. Gut 1998, 43:29-32.
42. Higgins P.D., Schwartz M., Mapili J., et al. Is endoscopy necessary for the measurement of disease activity in ulcerative colitis?. Am J Gastroenterol 2005, 100:355-361.
43. Maunder R.G., Greenberg G.R. Comparison of a disease activity index and patients' self-reported symptom severity in ulcerative colitis. Inflamm Bowel Dis 2004, 10:632-636.
44. Lichtiger S., Present D.H. Preliminary report: cyclosporin in treatment of severe active ulcerative colitis. Lancet 1990, 336:16-19.
45. Seo M., Okada M., Yao T., et al. An index of disease activity in patients with ulcerative colitis. Am J Gastroenterol 1992, 87:971-976.
46. Azzolini F., Pagnini C., Camellini L., et al. Proposal of a new clinical index predictive of endoscopic severity in ulcerative colitis. Dig Dis Sci 2005, 50:246-251.
47. Travis S.P., Schnell D., Krzeski P., et al. Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS). Gut 2012, 61:535-542.
48. Peyrin-Biroulet L., Fiorino G., Buisson A., et al. First-line therapy in adult Crohn's disease: who should receive anti-TNF agents?. Nat Rev Gastroenterol Hepatol 2013, 10:345-351.
49. Berrill J.W., Green J.T., Hood K., et al. Symptoms of irritable bowel syndrome in patients with inflammatory bowel disease: examining the role of sub-clinical inflammation and the impact on clinical assessment of disease activity. Aliment Pharmacol Ther 2013, 38:44-51.
50. Calabrese E., Zorzi F., Zuzzi S., et al. Development of a numerical index quantitating small bowel damage as detected by ultrasonography in Crohn's disease. J Crohns Colitis 2012, 6:852-860.
51. Ripolles T., Martinez M.J., Paredes J.M., et al. Crohn disease: correlation of findings at contrast-enhanced US with severity at endoscopy. Radiology 2009, 253:241-248.
52. Rimola J., Rodriguez S., Garcia-Bosch O., et al. Magnetic resonance for assessment of disease activity and severity in ileocolonic Crohn's disease. Gut 2009, 58:1113-1120.
53. Rimola J., Ordas I., Rodriguez S., et al. Magnetic resonance imaging for evaluation of Crohn's disease: validation of parameters of severity and quantitative index of activity. Inflamm Bowel Dis 2011, 17:1759-1768.
54. Oussalah A., Laurent V., Bruot O., et al. Diffusion-weighted magnetic resonance without bowel preparation for detecting colonic inflammation in inflammatory bowel disease. Gut 2010, 59:1056-1065.
55. Gallego J.C., Echarri A.I., Porta A., et al. Ileal Crohn's disease: MRI with endoscopic correlation. Eur J Radiol 2011, 80:e8-e12.
56. Girometti R., Zuiani C., Toso F., et al. MRI scoring system including dynamic motility evaluation in assessing the activity of Crohn's disease of the terminal ileum. Acad Radiol 2008, 15:153-164.
57. Van Assche G., Herrmann K.A., Louis E., et al. Effects of infliximab therapy on transmural lesions as assessed by magnetic resonance enteroclysis in patients with ileal Crohn's disease. J Crohns Colitis 2013, 7:950-957.
58. Sailer J., Peloschek P., Reinisch W., et al. Anastomotic recurrence of Crohn's disease after ileocolic resection: comparison of MR enteroclysis with endoscopy. Eur Radiol 2008, 18:2512-2521.
59. Koilakou S., Sailer J., Peloschek P., et al. Endoscopy and MR enteroclysis: equivalent tools in predicting clinical recurrence in patients with Crohn's disease after ileocolic resection. Inflamm Bowel Dis 2010, 16:198-203.
60. Hurlstone D.P., Sanders D.S., Lobo A.J., et al. Prospective evaluation of high-frequency mini-probe ultrasound colonoscopic imaging in ulcerative colitis: a valid tool for predicting clinical severity. Eur J Gastroenterol Hepatol 2005, 17:1325-1331.
61. Ordas I., Rimola J., Garcia-Bosch O., et al. Diagnostic accuracy of magnetic resonance colonography for the evaluation of disease activity and severity in ulcerative colitis: a prospective study. Gut 2013, 62:1566-1572.
62. Korelitz B.I., Sultan K., Kothari M., et al. Histological healing favors lower risk of colon carcinoma in extensive ulcerative colitis. World J Gastroenterol 2014, 20:4980-4986.
63. Riley S.A., Mani V., Goodman M.J., et al. Microscopic activity in ulcerative colitis: what does it mean?. Gut 1991, 32:174-178.
64. Geboes K., Riddell R., Ost A., et al. A reproducible grading scale for histological assessment of inflammation in ulcerative colitis. Gut 2000, 47:404-409.
65. Lemmens B., Arijs I., Van Assche G., et al. Correlation between the endoscopic and histologic score in assessing the activity of ulcerative colitis. Inflamm Bowel Dis 2013, 19:1194-1201.
66. Gupta R.B., Harpaz N., Itzkowitz S., et al. Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study. Gastroenterology 2007, 133:1099-1105.
67. Bessho R., Kanai T., Hosoe N., et al. Correlation between endocytoscopy and conventional histopathology in microstructural features of ulcerative colitis. J Gastroenterol 2011, 46:1197-1202.
68. Torres J., Billioud V., Sachar D.B., et al. Ulcerative colitis as a progressive disease: the forgotten evidence. Inflamm Bowel Dis 2012, 18:1356-1363.
69. Beaugerie L., Seksik P., Nion-Larmurier I., et al. Predictors of Crohn's disease. Gastroenterology 2006, 130:650-656.
70. Loly C., Belaiche J., Louis E. Predictors of severe Crohn's disease. Scand J Gastroenterol 2008, 43:948-954.
71. Solberg I.C., Vatn M.H., Hoie O., et al. Clinical course in Crohn's disease: results of a Norwegian population-based ten-year follow-up study. Clin Gastroenterol Hepatol 2007, 5:1430-1438.
72. Peyrin-Biroulet L., Harmsen W.S., Tremaine W.J., et al. Surgery in a population-based cohort of Crohn's disease from Olmsted County, Minnesota (1970-2004). Am J Gastroenterol 2012, 107:1693-1701.
73. Veloso F.T., Ferreira J.T., Barros L., et al. Clinical outcome of Crohn's disease: analysis according to the Vienna classification and clinical activity. Inflamm Bowel Dis 2001, 7:306-313.
74. Sands B.E., Arsenault J.E., Rosen M.J., et al. Risk of early surgery for Crohn's disease: implications for early treatment strategies. Am J Gastroenterol 2003, 98:2712-2718.
75. Ryan J.D., Silverberg M.S., Xu W., et al. Predicting complicated Crohn's disease and surgery: phenotypes, genetics, serology and psychological characteristics of a population-based cohort. Aliment Pharmacol Ther 2013, 38:274-283.
76. Mekhjian H.S., Switz D.M., Melnyk C.S., et al. Clinical features and natural history of Crohn's disease. Gastroenterology 1979, 77:898-906.
77. Wolters F.L., Russel M.G., Sijbrandij J., et al. Phenotype at diagnosis predicts recurrence rates in Crohn's disease. Gut 2006, 55:1124-1130.
78. Romberg-Camps M.J., Dagnelie P.C., Kester A.D., et al. Influence of phenotype at diagnosis and of other potential prognostic factors on the course of inflammatory bowel disease. Am J Gastroenterol 2009, 104:371-383.
79. Tarrant K.M., Barclay M.L., Frampton C.M., et al. Perianal disease predicts changes in Crohn's disease phenotype-results of a population-based study of inflammatory bowel disease phenotype. Am J Gastroenterol 2008, 103:3082-3093.
80. Henriksen M., Jahnsen J., Lygren I., et al. Are there any differences in phenotype or disease course between familial and sporadic cases of inflammatory bowel disease? Results of a population-based follow-up study. Am J Gastroenterol 2007, 102:1955-1963.
81. Henriksen M., Jahnsen J., Lygren I., et al. C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study. Gut 2008, 57:1518-1523.
82. Kiss L.S., Papp M., Lovasz B.D., et al. High-sensitivity C-reactive protein for identification of disease phenotype, active disease, and clinical relapses in Crohn's disease: a marker for patient classification?. Inflamm Bowel Dis 2012, 18:1647-1654.
83. Koelewijn C.L., Schwartz M.P., Samsom M., et al. C-reactive protein levels during a relapse of Crohn's disease are associated with the clinical course of the disease. World J Gastroenterol 2008, 14:85-89.
84. Solberg I.C., Lygren I., Cvancarova M., et al. Predictive value of serologic markers in a population-based Norwegian cohort with inflammatory bowel disease. Inflamm Bowel Dis 2009, 15:406-414.
85. Ferrante M., Henckaerts L., Joossens M., et al. New serological markers in inflammatory bowel disease are associated with complicated disease behaviour. Gut 2007, 56:1394-1403.
86. Vasiliauskas E.A., Kam L.Y., Karp L.C., et al. Marker antibody expression stratifies Crohn's disease into immunologically homogeneous subgroups with distinct clinical characteristics. Gut 2000, 47:487-496.
87. Henckaerts L., Van Steen K., Verstreken I., et al. Genetic risk profiling and prediction of disease course in Crohn's disease patients. Clin Gastroenterol Hepatol 2009, 7:972-980 e2.
88. Hampe J., Grebe J., Nikolaus S., et al. Association of NOD2 (CARD 15) genotype with clinical course of Crohn's disease: a cohort study. Lancet 2002, 359:1661-1665.
89. Ahmad T., Armuzzi A., Bunce M., et al. The molecular classification of the clinical manifestations of Crohn's disease. Gastroenterology 2002, 122:854-866.
90. Seiderer J., Brand S., Herrmann K.A., et al. Predictive value of the CARD15 variant 1007fs for the diagnosis of intestinal stenoses and the need for surgery in Crohn's disease in clinical practice: results of a prospective study. Inflamm Bowel Dis 2006, 12:1114-1121.
91. Cleynen I., Gonzalez J.R., Figueroa C., et al. Genetic factors conferring an increased susceptibility to develop Crohn's disease also influence disease phenotype: results from the IBDchip European Project. Gut 2013, 62:1556-1565.
92. Solberg I.C., Lygren I., Jahnsen J., et al. Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study). Scand J Gastroenterol 2009, 44:431-440.
93. Langholz E., Munkholm P., Davidsen M., et al. Colorectal cancer risk and mortality in patients with ulcerative colitis. Gastroenterology 1992, 103:1444-1451.
94. Hoie O., Wolters F., Riis L., et al. Ulcerative colitis: patient characteristics may predict 10-yr disease recurrence in a European-wide population-based cohort. Am J Gastroenterol 2007, 102:1692-1701.
95. Szamosi T., Banai J., Lakatos L., et al. Early azathioprine/biological therapy is associated with decreased risk for first surgery and delays time to surgery but not reoperation in both smokers and nonsmokers with Crohn's disease, while smoking decreases the risk of colectomy in ulcerative colitis. Eur J Gastroenterol Hepatol 2010, 22:872-879.
96. Hoie O., Aamodt G., Vermeire S., et al. Serological markers are associated with disease course in ulcerative colitis. A study in an unselected population-based cohort followed for 10 years. J Crohns Colitis 2008, 2:114-122.
97. Lasson A., Simren M., Stotzer P.O., et al. Fecal calprotectin levels predict the clinical course in patients with new onset of ulcerative colitis. Inflamm Bowel Dis 2013, 19:576-581.
98. Ekbom A., Helmick C., Zack M., et al. Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med 1990, 323:1228-1233.
99. Lutgens M.W., van Oijen M.G., van der Heijden G.J., et al. Declining risk of colorectal cancer in inflammatory bowel disease: an updated meta-analysis of population-based cohort studies. Inflamm Bowel Dis 2013, 19:789-799.
100. Jess T., Simonsen J., Jorgensen K.T., et al. Decreasing risk of colorectal cancer in patients with inflammatory bowel disease over 30 years. Gastroenterology 2012, 143:375-381.
101. Parisian K.R., Lopez R., Shen B. Chronic pouch inflammation and risk for new-onset extraintestinal cancers in patients with restorative proctocolectomy for ulcerative colitis. Inflamm Bowel Dis 2013, 19:806-811.
102. Best W.R., Becktel J.M., Singleton J.W., et al. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 1976, 70:439-444.
103. Lichtenstein G.R., Hanauer S.B., Sandborn W.J., et al. Management of Crohn's disease in adults. Am J Gastroenterol 2009, 104:465-483. quiz 64, 84.
104. Van Assche G., Dignass A., Panes J., et al. The second European evidence-based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis. J Crohns Colitis 2010, 4:7-27.
105. Truelove S.C., Witts L.J. Cortisone in ulcerative colitis; final report on a therapeutic trial. BMJ 1955, 2:1041-1048.
106. Kornbluth A., Sachar D.B. Practice Parameters Committee of the American College of Gastroenterology. Ulcerative colitis practice guidelines in adults. Am J Gastroenterol 2010, 105:501-523.
107. Dignass A., Eliakim R., Magro F., et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosis. J Crohns Colitis 2012, 6:965-990.
108. Sandborn W.J., Feagan B.G., Hanauer S.B., et al. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. Gastroenterology 2002, 122:512-530.
109. Thia K., Faubion W.A., Loftus E.V., et al. Short CDAI: development and validation of a shortened and simplified Crohn's disease activity index. Inflamm Bowel Dis 2011, 17:105-111.
110. Khanna R., D'Haens G., Feagan B., et al. Patient reported outcome measures derived from the Crohn's Disease Activity Index: correlation between PRO2 and PRO3 scores and CDAI-defined clinical thresholds (abstr). ECCO 2014, 2014:P176.
111. Best W.R. Predicting the Crohn's disease activity index from the Harvey-Bradshaw Index. Inflamm Bowel Dis 2006, 12:304-310.
112. Harvey R.F., Bradshaw J.M. A simple index of Crohn's-disease activity. Lancet 1980, 1:514.
113. van Hees P.A., van Elteren P.H., van Lier H.J., et al. An index of inflammatory activity in patients with Crohn's disease. Gut 1980, 21:279-286.
114. Irvine E.J. Usual therapy improves perianal Crohn's disease as measured by a new disease activity index. McMaster IBD Study Group. J Clin Gastroenterol 1995, 20:27-32.
115. Losco A., Vigano C., Conte D., et al. Assessing the activity of perianal Crohn's disease: comparison of clinical indices and computer-assisted anal ultrasound. Inflamm Bowel Dis 2009, 15:742-749.
116. Schroeder K.W., Tremaine W.J., Ilstrup D.M. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 1987, 317:1625-1629.
117. Sutherland L.R., Martin F., Greer S., et al. 5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology 1987, 92:1894-1898.
118. Poole C.D., Connolly M.P., Nielsen S.K., et al. A comparison of physician-rated disease severity and patient reported outcomes in mild to moderately active ulcerative colitis. J Crohns Colitis 2010, 4:275-282.
119. Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ 1989, 298:82-86.
120. Schoepfer A.M., Beglinger C., Straumann A., et al. Ulcerative colitis: correlation of the Rachmilewitz endoscopic activity index with fecal calprotectin, clinical activity, C-reactive protein, and blood leukocytes. Inflamm Bowel Dis 2009, 15:1851-1858.
121. Powell-Tuck J., Day D.W., Buckell N.A., et al. Correlations between defined sigmoidoscopic appearances and other measures of disease activity in ulcerative colitis. Dig Dis Sci 1982, 27:533-537.
122. Bossa F., Latiano A., Rossi L., et al. Erythrocyte-mediated delivery of dexamethasone in patients with mild-to-moderate ulcerative colitis, refractory to mesalamine: a randomized, controlled study. Am J Gastroenterol 2008, 103:2509-2516.
123. Walmsley R.S., Ayres R.C., Pounder R.E., et al. A simple clinical colitis activity index. Gut 1998, 43:29-32.
124. Turner D., Seow C.H., Greenberg G.R., et al. A systematic prospective comparison of noninvasive disease activity indices in ulcerative colitis. Clin Gastroenterol Hepatol 2009, 7:1081-1088.
125. Higgins P.D., Schwartz M., Mapili J., et al. Patient defined dichotomous end points for remission and clinical improvement in ulcerative colitis. Gut 2005, 54:782-788.
126. Lichtiger S., Present D.H. Preliminary report: cyclosporin in treatment of severe active ulcerative colitis. Lancet 1990, 336:16-19.
127. Schoepfer A.M., Beglinger C., Straumann A., et al. Fecal calprotectin more accurately reflects endoscopic activity of ulcerative colitis than the Lichtiger Index, C-reactive protein, platelets, hemoglobin, and blood leukocytes. Inflamm Bowel Dis 2013, 19:332-341.
128. Seo M., Okada M., Yao T., et al. An index of disease activity in patients with ulcerative colitis. Am J Gastroenterol 1992, 87:971-976.
129. Seo M., Okada M., Maeda K., et al. Correlation between endoscopic severity and the clinical activity index in ulcerative colitis. Am J Gastroenterol 1998, 93:2124-2129.
130. Turner D., Leach S.T., Mack D., et al. Faecal calprotectin, lactoferrin, M2-pyruvate kinase and S100A12 in severe ulcerative colitis: a prospective multicentre comparison of predicting outcomes and monitoring response. Gut 2010, 59:1207-1212.
131. af Bjorkesten C.G., Nieminen U., Turunen U., et al. Surrogate markers and clinical indices, alone or combined, as indicators for endoscopic remission in anti-TNF-treated luminal Crohn's disease. Scand J Gastroenterol 2012, 47:528-537.
132. Walters T.D., Steinhart A.H., Bernstein C.N., et al. Validating Crohn's disease activity indices for use in assessing postoperative recurrence. Inflamm Bowel Dis 2011, 17:1547-1556.
133. Lewis J.D., Chuai S., Nessel L., et al. Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis. Inflamm Bowel Dis 2008, 14:1660-1666.
134. Guyatt G., Mitchell A., Irvine E.J., et al. A new measure of health status for clinical trials in inflammatory bowel disease. Gastroenterology 1989, 96:804-810.
135. Irvine E.J. Development and subsequent refinement of the inflammatory bowel disease questionnaire: a quality-of-life instrument for adult patients with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 1999, 28:S23-S27.
136. Love J.R., Irvine E.J., Fedorak R.N. Quality of life in inflammatory bowel disease. J Clin Gastroenterol 1992, 14:15-19.
137. Hlavaty T., Persoons P., Vermeire S., et al. Evaluation of short-term responsiveness and cutoff values of inflammatory bowel disease questionnaire in Crohn's disease. Inflamm Bowel Dis 2006, 12:199-204.
138. Huaman J.W., Casellas F., Borruel N., et al. Cutoff values of the Inflammatory Bowel Disease Questionnaire to predict a normal health related quality of life. J Crohns Colitis 2010, 4:637-641.
139. Clara I., Lix L.M., Walker J.R., et al. The Manitoba IBD Index: evidence for a new and simple indicator of IBD activity. Am J Gastroenterol 2009, 104:1754-1763.
140. Surti B., Spiegel B., Ippoliti A., et al. Assessing health status in inflammatory bowel disease using a novel single-item numeric rating scale. Dig Dis Sci 2013, 58:1313-1321.
141. Bodger K., Ormerod C., Shackcloth D., et al. Development and validation of a rapid, generic measure of disease control from the patient's perspective: the IBD-control questionnaire. Gut 2014, 63:1092-1102.
142. Chamouard P., Richert Z., Meyer N., et al. Diagnostic value of C-reactive protein for predicting activity level of Crohn's disease. Clin Gastroenterol Hepatol 2006, 4:882-887.
143. Karoui S., Ouerdiane S., Serghini M., et al. Correlation between levels of C-reactive protein and clinical activity in Crohn's disease. Dig Liver Dis 2007, 39:1006-1010.
144. Sipponen T., Savilahti E., Kolho K.L., et al. Crohn's disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn's disease activity index and endoscopic findings. Inflamm Bowel Dis 2008, 14:40-46.
145. Schoepfer A.M., Beglinger C., Straumann A., et al. Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn's disease (SES-CD) than CRP, blood leukocytes, and the CDAI. Am J Gastroenterol 2010, 105:162-169.
146. Nancey S., Boschetti G., Moussata D., et al. Neopterin is a novel reliable fecal marker as accurate as calprotectin for predicting endoscopic disease activity in patients with inflammatory bowel diseases. Inflamm Bowel Dis 2013, 19:1043-1052.
147. D'Haens G., Ferrante M., Vermeire S., et al. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis 2012, 18:2218-2224.
148. Husain N., Tokoro K., Popov J.M., et al. Neopterin concentration as an index of disease activity in Crohn's disease and ulcerative colitis. J Clin Gastroenterol 2013, 47:246-251.
149. Mary J.Y., Modigliani R. Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes Therapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). Gut 1989, 30:983-989.
150. Sipponen T., Nuutinen H., Turunen U., et al. Endoscopic evaluation of Crohn's disease activity: comparison of the CDEIS and the SES-CD. Inflamm Bowel Dis 2010, 16:2131-2136.
151. Daperno M., D'Haens G., Van Assche G., et al. Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD. Gastrointest Endosc 2004, 60:505-512.
152. Moskovitz D.N., Daperno M., Van Assche G. Defining and validating cut-offs for the Simple Endoscopic Score for Crohn's disease. Gastoenterology 2007, 132:S1097.
153. Gralnek I.M., Defranchis R., Seidman E., et al. Development of a capsule endoscopy scoring index for small bowel mucosal inflammatory change. Aliment Pharmacol Ther 2008, 27:146-154.
154. Travis S.P., Schnell D., Krzeski P., et al. Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS). Gut 2012, 61:535-542.
155. Beaugerie L., Seksik P., Nion-Larmurier I., et al. Predictors of Crohn's disease. Gastroenterology 2006, 130:650-656.
156. Loly C., Belaiche J., Louis E. Predictors of severe Crohn's disease. Scand J Gastroenterol 2008, 43:948-954.
157. Solberg I.C., Vatn M.H., Hoie O., et al. Clinical course in Crohn's disease: results of a Norwegian population-based ten-year follow-up study. Clin Gastroenterol Hepatol 2007, 5:1430-1438.
158. Henriksen M., Jahnsen J., Lygren I., et al. C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study. Gut 2008, 57:1518-1523.
159. Romberg-Camps M.J., Dagnelie P.C., Kester A.D., et al. Influence of phenotype at diagnosis and of other potential prognostic factors on the course of inflammatory bowel disease. Am J Gastroenterol 2009, 104:371-383.
160. Wolters F.L., Russel M.G., Sijbrandij J., et al. Phenotype at diagnosis predicts recurrence rates in Crohn's disease. Gut 2006, 55:1124-1130.
161. Peyrin-Biroulet L., Harmsen W.S., Tremaine W.J., et al. Surgery in a population-based cohort of Crohn's disease from Olmsted County, Minnesota (1970-2004). Am J Gastroenterol 2012, 107:1693-1701.
162. Veloso F.T., Ferreira J.T., Barros L., et al. Clinical outcome of Crohn's disease: analysis according to the Vienna classification and clinical activity. Inflamm Bowel Dis 2001, 7:306-313.
163. Sands B.E., Arsenault J.E., Rosen M.J., et al. Risk of early surgery for Crohn's disease: implications for early treatment strategies. Am J Gastroenterol 2003, 98:2712-2718.
164. Tarrant K.M., Barclay M.L., Frampton C.M., et al. Perianal disease predicts changes in Crohn's disease phenotype-results of a population-based study of inflammatory bowel disease phenotype. Am J Gastroenterol 2008, 103:3082-3093.
165. Thia K.T., Sandborn W.J., Harmsen W.S., et al. Risk factors associated with progression to intestinal complications of Crohn's disease in a population-based cohort. Gastroenterology 2010, 139:1147-1155.
166. Allez M., Lemann M., Bonnet J., et al. Long term outcome of patients with active Crohn's disease exhibiting extensive and deep ulcerations at colonoscopy. Am J Gastroenterol 2002, 97:947-953.
167. Mekhjian H.S., Switz D.M., Melnyk C.S., et al. Clinical features and natural history of Crohn's disease. Gastroenterology 1979, 77:898-906.
168. Kiss L.S., Papp M., Lovasz B.D., et al. High-sensitivity C-reactive protein for identification of disease phenotype, active disease, and clinical relapses in Crohn's disease: a marker for patient classification?. Inflamm Bowel Dis 2012, 18:1647-1654.
169. Ryan J.D., Silverberg M.S., Xu W., et al. Predicting complicated Crohn's disease and surgery: phenotypes, genetics, serology and psychological characteristics of a population-based cohort. Aliment Pharmacol Ther 2013, 38:274-283.
170. Szamosi T., Banai J., Lakatos L., et al. Early azathioprine/biological therapy is associated with decreased risk for first surgery and delays time to surgery but not reoperation in both smokers and nonsmokers with Crohn's disease, while smoking decreases the risk of colectomy in ulcerative colitis. Eur J Gastroenterol Hepatol 2010, 22:872-879.
171. Koelewijn C.L., Schwartz M.P., Samsom M., et al. C-reactive protein levels during a relapse of Crohn's disease are associated with the clinical course of the disease. World J Gastroenterol 2008, 14:85-89.
172. Solberg I.C., Lygren I., Cvancarova M., et al. Predictive value of serologic markers in a population-based Norwegian cohort with inflammatory bowel disease. Inflamm Bowel Dis 2009, 15:406-414.
173. Vasiliauskas E.A., Kam L.Y., Karp L.C., et al. Marker antibody expression stratifies Crohn's disease into immunologically homogeneous subgroups with distinct clinical characteristics. Gut 2000, 47:487-496.
174. Ferrante M., Henckaerts L., Joossens M., et al. New serological markers in inflammatory bowel disease are associated with complicated disease behaviour. Gut 2007, 56:1394-1403.
175. Henckaerts L., Van Steen K., Verstreken I., et al. Genetic risk profiling and prediction of disease course in Crohn's disease patients. Clin Gastroenterol Hepatol 2009, 7:972-980 e2.
176. Hampe J., Grebe J., Nikolaus S., et al. Association of NOD2 (CARD 15) genotype with clinical course of Crohn's disease: a cohort study. Lancet 2002, 359:1661-1665.
177. Ahmad T., Armuzzi A., Bunce M., et al. The molecular classification of the clinical manifestations of Crohn's disease. Gastroenterology 2002, 122:854-866.
178. Seiderer J., Brand S., Herrmann K.A., et al. Predictive value of the CARD15 variant 1007fs for the diagnosis of intestinal stenoses and the need for surgery in Crohn's disease in clinical practice: results of a prospective study. Inflamm Bowel Dis 2006, 12:1114-1121.
179. Lasson A., Simren M., Stotzer P.O., et al. Fecal calprotectin levels predict the clinical course in patients with new onset of ulcerative colitis. Inflamm Bowel Dis 2013, 19:576-581.
180. Henriksen M., Jahnsen J., Lygren I., et al. Are there any differences in phenotype or disease course between familial and sporadic cases of inflammatory bowel disease? Results of a population-based follow-up study. Am J Gastroenterol 2007, 102:1955-1963.
181. Hoie O., Wolters F., Riis L., et al. Ulcerative colitis: patient characteristics may predict 10-yr disease recurrence in a European-wide population-based cohort. Am J Gastroenterol 2007, 102:1692-1701.
182. Ekbom A., Helmick C., Zack M., et al. Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med 1990, 323:1228-1233.
183. Lutgens M.W., van Oijen M.G., van der Heijden G.J., et al. Declining risk of colorectal cancer in inflammatory bowel disease: an updated meta-analysis of population-based cohort studies. Inflamm Bowel Dis 2013, 19:789-799.
184. Jess T., Simonsen J., Jorgensen K.T., et al. Decreasing risk of colorectal cancer in patients with inflammatory bowel disease over 30 years. Gastroenterology 2012, 143:375-381.
185. Solberg I.C., Lygren I., Jahnsen J., et al. Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study). Scand J Gastroenterol 2009, 44:431-440.
186. Langholz E., Munkholm P., Davidsen M., et al. Colorectal cancer risk and mortality in patients with ulcerative colitis. Gastroenterology 1992, 103:1444-1451.
187. Hoie O., Aamodt G., Vermeire S., et al. Serological markers are associated with disease course in ulcerative colitis. A study in an unselected population-based cohort followed for 10 years. J Crohns Colitis 2008, 2:114-122.